nach oben

04.04.2024 | Gynäkoonkologie

Therapiealgorithmen beim Ovarial-, Zervix- und Endometriumkarzinom

Richtig behandeln in der fortgeschrittenen Situation

verfasst von: PD Dr. Kathrin Strasser-Weippl, Dr. Lea Korber

Einloggen, um Zugang zu erhalten

Auszug

Zu den bereits bekannten Therapiemöglichkeiten beim fortgeschrittenen Ovarial-, Zervix- oder Endometriumkarzinom haben sich in den letzten Jahren weitere neue Substanzen gesellt - etwa die Immuncheckpointinhibitoren. Ein Blick in die aktuelle Studienlandschaft lässt erahnen, dass die Optimierung der Behandlung noch nicht abgeschlossen ist. …

S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. AWMF-Registernr.: 032-035OL

Gonzáles-Martín A et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2023;34(10):833-48

Burger R et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 2011;365(26):2473

Monk BJ et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapyas Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ ENGOT-ov45). J Clin Oncol. 2022;40(34):3952-64

González-Martín A et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391-402

Tew WP et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(30):3468-93

Ray-Coquard I et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2428

Sznurkowski JJ. To Bev or Not to Bev during Ovarian Cancer Maintenance Therapy? Cancers (Basel). 2023;15(11):2980

Harter P et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol. 2023; https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA5506

10.

Raja FA et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol. 2013;24(12):3028-34

11.

Harter P. et al. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021;385(23):2123-31

12.

Pignata S et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021;22(2):267-76

13.

Tew WP et al. Poly (ADP-Ribose) Polymerase Inhibitors in the management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2022;40(33):3878-81

14.

Pujade-Lauraine E et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-8

15.

Moore KN et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023;389(23):2162-74

16.

S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom. AWMF-Registernr.: 032/033OL

17.

Long HJ et al. Randomized Phase III Trial of Cisplatin with or Without Topotecanin Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. J Clin Oncol. 2005;23(21):4626-33

18.

Tewari KS et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med. 2014;370(8):734-43

19.

Colombo N et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856-67

20.

Maio M et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929-38

21.

Bogani G et al. Tisotumab Vedotin in recurrent or metastatic cervical cancer. Curr Probl Cancer. 2023;47(3):100952

22.

Tewari KS et al. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022;386(6):544-55

23.

Oaknin A et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860-77

24.

Mirza MR et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145-58

25.

Eskander R. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388:2159-70

26.

O'Malley D et al. Pembrolizumab in Patients with Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol. 2022;40(7):752-61

27.

Oaknin A et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777

28.

Makker V et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022;386(5):437-48

29.

Meric-Bernstam F et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024;42(1):47-58

Titel: Therapiealgorithmen beim Ovarial-, Zervix- und Endometriumkarzinom
Richtig behandeln in der fortgeschrittenen Situation
verfasst von: PD Dr. Kathrin Strasser-Weippl
Dr. Lea Korber
Publikationsdatum: 04.04.2024
Verlag: Springer Medizin
DOI: https://doi.org/10.1007/s15015-024-3785-6

Springer Medizin Österreich

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten